Jon Napitupulu

Metagenomi Therapeutics (Nasdaq: MGX) reported full-year 2025 results, unveiled a corporate rebrand, and detailed clinical readiness steps for its...

Camp4 Therapeutics reported full-year 2025 results, advanced its lead SYNGAP1 program toward first-in-human testing, secured a discovery-stage collaboration with...

BridgeBio Oncology Therapeutics reported fourth‑quarter and full‑year 2025 results and, more importantly for the market, unveiled early clinical signals...

aTyr Pharma will meet the FDA in mid-April 2026 to review mixed Phase 3 results for efzofitimod in pulmonary...

Kuva Labs has signed a definitive agreement to acquire Lisata Therapeutics via a tender offer at $5.00 per share...

UroGen Pharma has granted inducement restricted stock units to 11 new hires, covering up to 51,200 ordinary shares that...

CytomX Therapeutics will report full-year 2025 results on March 16, 2026, before U.S. market open, followed by a webcasted...

TScan Therapeutics plans to initiate its first Phase 3 trial in the second quarter of 2026 for TSC-101 to...

Kamada will report fourth-quarter and full-year 2025 results on March 11, 2026, and host an investor call that morning....

EyePoint, Inc. reported year-end 2025 results and advanced its lead asset Duravyu, a bioerodible intravitreal insert of the TKI...